Time-Restricted Feeding on Glucose Homeostasis and Quality of Life
NCT ID: NCT04062773
Last Updated: 2019-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2019-07-10
2020-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Plan of investigation: Participants meeting the eligibility criteria will be randomized to the TRF arm or the continuous eating arm. Both arms with be given a prescribed dietary plan to help them lose 5% of body weight. In the TRF they will permitted to eat between midday and 6pm. In the continuous eating arm they will be allowed to eat between 8am and 11pm. Participants will attend the nutrition clinic every two weeks to be weighed and be given personalized support to help them follow their assigned diet. Prior to starting the diets outcome measures will be taken: Glycaemia will be measured by a glucose tolerance test, and 7-day continuous glucose monitoring. HbA1c will be taken from fasting blood sample. In addition, the fasting sample will be taken for measurement of insulin, lipid profile and inflammatory markers. We will also use questionnaires to assess quality of life, a 3-day food diary to assess compliance to diet especially meal timings. Capillary ketones will also be used to assess whether compliance to the assigned fasting period. Outcome measures will also be taken during 7 days of the second month, and then the final seven days of the last month on the diet. The primary outcome is HbA1c.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
12-week parallel randomised control trial
Recruitment
We will recruit via advertisements outside Dasman using social media and local ads in addition to screening of Dasman Registry for any potential participants. Opportunistic recruitment will also occur by DDI dietitians. Following telephone screening to ensure the potential participant meets initial screening criteria we will carry out a medical screening to ensure the person can take part.
Environment All screening, dietary counselling visits, and placement of the CGM will take place at the Dasman Diabetes Institute (DDI). The institute has extensive space for interventional studies, including screening rooms, body composition assessment and clinical rooms for placement of the CGM monitor.
STUDY INTERVENTIONS
For both groups all participants will be guided towards a 5% weight loss based on individualised energy requirements. The difference will be the hours during which the participants consume their required calories.
* Time restricted feeding group: Will consume their calories between 12pm and 6pm.
* Continuous energy restriction group: Will consume their calories between 8am and 11pm.
Participants will be guided towards their weight loss during one-to-one visits at baseline and every 2 weeks for 12 weeks.
Procedures
* At baseline and follow-up all participants will undergo an oral glucose tolerance test.
* A blood sample will also be taken for HbA1c, lipid profile, fasting insulin, inflammatory factors and a sample for Biobank. The biobank sample will be stored to enable us, with other researchers at DDI to understand the heterogeneity of type 2 diabetes; whether certain people respond to dietary interventions based on their genetic, epigenetic or metabolomic background; and ultimately will help guide clinical care.
* Participants will wear Flash Glucose monitoring or other continuous glucose monitoring device to measure their 24-hour blood glucose concentrations during the seven days preceding the start of the dietary intervention, seven days of the second month, and the final seven days of the third month.
* Participants will also measure their capillary ketones during the first three days of the first month, three days of the second month, and final three days of the third month.
* Medication changes: prandial medications (insulin or sulphonylurea) will be altered to the timing of meal intake. Any reduction in medication due to changes in glucose will be carried out by the patient's doctor.
* A quality of life questionnaire: PAID.
* A 3 day food diary with meal times to check compliance.
Statistical Methods
This is a pilot study. We will recruit 25 people per group. This is based on recommendations for sample sizes for feasibility and pilot studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TRF
Eating restricted to between midday and 6pm.
TRF
time restricted feeding group
Normal timing of food intake.
Eating between 8am and 11pm.
Normal timing of food intake
no time restricted feeding
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TRF
time restricted feeding group
Normal timing of food intake
no time restricted feeding
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 21-65 years
* T2DM with any diabetes medication
* BMI of 25-45 kg/m2
* Wake up at a regular time between 5-8 am
* Able to provide informed consent.
Exclusion Criteria
* HbA1c of \<6ยท5% and \>12%
* Serious current or recent illness including cancer or severe or unstable heart failure.
* Participation in another clinical research trial.
* Current treatment with anti-obesity drugs.
* Substance abuse
* Learning difficulties
* Presence of an eating disorder
* Purging behaviour
* Pregnancy or consideration of pregnancy
* Hospital admission for depression or use of antipsychotic drugs.
* Regularly eat within a \<9-hour period each day
* Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
21 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dasman Diabetes Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Ebaa Al Ozairi
Chief Medical Officer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dasman Diabetes Institute
Kuwait City, , Kuwait
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nicola Guess, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RA HM-2019-012
Identifier Type: -
Identifier Source: org_study_id